Baptist Health Hamburg

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Colorectal cancer3 trials
• Triple-negative breast cancer2 trials
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 37 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Recruiting11 trials
• Active, not recruiting3 trials

Lead sponsor

• SWOG Cancer Research Network4 trials
• Alliance for Clinical Trials in Oncology2 trials
• National Cancer Institute (NCI)2 trials
• NRG Oncology2 trials
• Bristol-Myers Squibb1 trial
• and 3 more

Running trials

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

  Contact: Firas Badin, Site 0171

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  NCT06769126· Phase 2· SWOG Cancer Research Network· Source

  Contact: Firas B. Badin (principal investigator)

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Firas Badin (principal investigator)

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

  Contact: Mounika Mandadi (principal investigator)

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· SWOG Cancer Research Network· Source

  Contact: Mounika Mandadi (principal investigator)

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Mounika Mandadi (principal investigator)

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

  Contact: Lee G. Hicks (principal investigator)

• Active, not recruiting

  Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04625647· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Firas B. Badin (principal investigator)

• Recruiting

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source

  Contact: Firas B. Badin (principal investigator)

• Active, not recruiting

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Colorectal cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting